The next-generation psychedelics R&D business is up and running, as BetterLife Pharma Inc. (OTCQB: BETRF)’s lead drug candidate LSD analog BETR-001 has shown positive results in a study assessing it as a potential treatment for mood disorders. 

In preclinical and IND-enabling studies, BETR-001 is a non-hallucinogenic and non-controlled LSD derivative with the potential for self-administration, which BetterLife is aiming to patent for the treatment of Major Depressive Disorder (MDD,) anxiety disorder and neuropathic pain, among other conditions.

These outcomes of 2-bromo-LSD or BETR-001’s therapy, published in the peer-reviewed journal Cell Report, further support previous positive data through an extensive pharmacological …

Full story available on